Skip to main content
    T

    Twist Bioscience Corp (TWST)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $105.04
    -6.56 (-5.88%)

    Market Cap: $7.40B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Twist Bioscience Corp (TWST) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Twist Bioscience (TWST) to earn -$0.40 per share in the fiscal year ending Sep 30, 2027, on revenue of $548.67M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Sep 30, 2027 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.23, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.

    RatingAnalystsShare
    Strong Buy215.4%
    Buy753.8%
    Hold323.1%
    Sell17.7%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 17.7%.

    Fiscal year ending Sep 30, 2027
    -$0.40
    EPS consensus, revenue $548.67M
    Fiscal year ending Sep 30, 2028
    $0.98
    EPS consensus, revenue $645.83M
    Next report
    Feb 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Sep 30, 2027-$0.40-$1.12 to $0.104$548.67M$532.40M to $559.88M11
    Sep 30, 2028$0.98$0.90 to $1.052$645.83M$628.36M to $662.30M9

    Quarterly Estimates

    The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.14-$0.31 to -$0.043$126.42M$124.00M to $128.13M8
    Mar 31, 2027-$0.11-$0.30 to $0.003$133.21M$130.10M to $136.32M8

    Estimate Revisions

    Across the 4 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Sep 30, 202710
    Fiscal year ending Sep 30, 202801
    Quarter ending Dec 31, 202610
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has improved from -$1.00.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Sep 30, 2027-$0.40-$0.75-$0.75-$0.78-$1.00N/A
    Fiscal year ending Sep 30, 2028$0.98$0.12$0.12$0.12-$0.03N/A
    Quarter ending Dec 31, 2026-$0.14-$0.16-$0.16-$0.16-$0.10N/A
    Quarter ending Mar 31, 2027-$0.11-$0.10-$0.10-$0.10-$0.06N/A

    Frequently Asked Questions About TWST

    What is the TWST stock forecast?

    Consensus analyst estimates put Twist Bioscience's EPS at -$0.40 for the fiscal year ending Sep 30, 2027, on revenue of $548.67M. The consensus rating from 13 analysts is Buy.

    How do analysts rate TWST stock?

    Of 13 analysts covering Twist Bioscience, 2 rate it Strong Buy, 7 Buy, 3 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TWST next year?

    For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$0.40, with estimates from -$1.12 to $0.10 from 4 analysts. For the fiscal year ending Sep 30, 2028, the consensus EPS estimate is $0.98, with estimates from $0.90 to $1.05 from 2 analysts.

    What revenue do analysts expect from Twist Bioscience next year?

    For the fiscal year ending Sep 30, 2027, the consensus revenue estimate is $548.67M, with estimates from $532.40M to $559.88M. For the fiscal year ending Sep 30, 2028, the consensus revenue estimate is $645.83M, with estimates from $628.36M to $662.30M.

    How many analysts cover TWST?

    13 analysts rate Twist Bioscience stock, and 4 analysts estimate its EPS for the fiscal year ending Sep 30, 2027.